Amiodarone-induced multiple organ damage in an Alström syndrome patient with end-stage renal disease and hepatic cirrhosis.
Alström syndrome (AS) is an extremely rare disease accompanied by blindness, hearing loss, obesity, type 2 diabetes, dilated cardiomyopathy, and progressive hepatic and renal dysfunction. The life span of AS patients rarely exceeds 50 years, and thus there are very few reports describing the implementation of renal replacement therapy for these patients. We here report a case of AS patient who exhibited dilated cardiomyopathy, end-stage renal disease, and hepatic cirrhosis. He underwent hemodialysis therapy more than 3 years. Although he eventually died of amiodarone-induced multiple organ damage in the lungs and liver, the present case suggests that hemodialysis therapy can be a choice of renal replacement therapy for AS patients with end-stage renal disease.
['Torimitsu|Takuto|T|', 'Yoshida|Tadashi|T|http://orcid.org/0000-0003-1626-7773', 'Makiuchi|Satomi|S|', 'Itoh|Hiroshi|H|', 'Oya|Mototsugu|M|']
End-stage renal disease Hepatic cirrhosis Amiodarone Hereditary kidney disease